Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 buff.ly/ucJRICC

Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabolic, nutraceuticals, TENS, acupuncture and biologics. buff.ly/1W1X9eg

Inflammatory vs. Noninflammatory Pain buff.ly/m00YY0f

SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. buff.ly/AIPUFjK

Best of 2025: Glossary for GCA Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving int'l experts. buff.ly/bIMsU6B

Best of 2025: Glucocorticoids in SLE: how to start, how to follow, how to stop Glucocorticoids work fast in SLE—but long-term harm is the tradeoff. Guidelines now push short-term “bridging therapy.” Great idea. Real-world execution still missing. buff.ly/R0RsYCm

Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society buff.ly/viww2Cx

Best of 2025: Distinguishing Septic and Gouty Arthritis A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed CA showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal threshold of 50,000 cells/mm3. buff.ly/44KS88s

Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. buff.ly/c6COFPw

Best of 2025: Dermatomyositis Reviewed Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options. rheumnow.com/news/best-20...

Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed infusions(RTX 1000 mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades 1, 2) infusion Rxns; only 6 Grade 3 Rxns buff.ly/vJHJbip

HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, buff.ly/ya8273f

JAMA -- Full read review "Uveitis in Adults:" - affects adults 20 to 50 years - noninfectious anterior uveitis: corticosteroids 1st line Rx - posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line buff.ly/4ho5dOI

Best of 2025: Vitamin D for Prevention of Disease JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults. rheumnow.com/news/best-20...

Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology? Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions. rheumnow.com/news/best-20...

APP Pearls “Get to know your patients and any barriers they have that may impact their healthcare” - Natalie Lane, FNP-C

2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. buff.ly/PSGJSdT

Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 buff.ly/lAS7D8u

“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and mortality” - Emma Bavage, NP

Best of 2025: Methotrexate intolerance in rheumatoid arthritis Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. rheumnow.com/news/best-20...

Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. buff.ly/hVo4I2U

Algorithm for the treatment of calcinosis #calcinosis #ACR24 buff.ly/4j2TK7A

Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. buff.ly/WKR2Xaz

Best of 2025: Overview of the VEXAS Syndrome A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome. rheumnow.com/news/best-20...

Inflammatory vs. Noninflammatory Pain buff.ly/m00YY0f

Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: buff.ly/6FgDrvD Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign #RheumTwitter #ILD #RheumX

APP Pearls “Do not order a test if you do not know how to interpret the results whether normal or abnormal” - Madison Chastain, CRNP

EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025

APP Pearls “Never stop learning—rheumatology is full of surprises” - Kayla Carlucci, FNP-BC

APP Pearls “You must assess sleep and mood- without this, even if you control all inflammation, you will not control pain and fatigue!” - Christine Stamatos, NP, DNP, RN

Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. buff.ly/hVo4I2U

Three Things to Know About Hiring, Onboarding, and Training APPs As the utilization of APPs (NPs and PAs) in rheumatology becomes more prevalent, here are three things to consider if you are thinking about adding an APP to your practice: Read on: rheumnow.com/news/three-t...

Telling You Where to Go (12.19.2025) Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients? rheumnow.com/news/telling...

Evaluation of Rheumatic Complaints rheumnow.com/resource/eva...

APP Controversies and Misconceptions In this Tuesday Night Rheumatology, panelists discuss a range of topics, including APP roles and impact; models of care; independence; seeing new patients and complex cases; and more. rheumnow.com/video/app-co...

Hidden in Plain Sight: IBD As a PA with 6 years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel disease. buff.ly/85HsmOZ

Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD). rheumnow.com/news/disease...

“Absence of proof of efficacy does not equal proof of absence of efficacy” - Arthur Kavanaugh, MD

FDA approved nerandomilast (Jascayd) for Tx of adults w/ progressive pulmonary fibrosis based on the the phase 3 FIBRONEER trial. Nerandomilast is PDE4 inhibitor,, in Oct 2026 it was approved for use in diopathic pulmonary fibrosis (IPF) www.boehringer-ingelheim.com/human-health...

Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. buff.ly/IlsvOTB

Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. buff.ly/Drrovfq

Evaluation of Rheumatic Complaints buff.ly/II3bal8

Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). arthritis-research.biomedcentral.com/articles/10....

Evaluation of Rheumatic Complaints rheumnow.com/resource/eva...

MEDISPO study of 38 mild-mod psoriasis pts, 16-wk Mediterranean diet vs low-fat diet. Mediterranean diet did much better w/ PASI change −3.4 vs 0, more pts achieving a PASI 75 reduction (47.4% vs none) jamanetwork.com/journals/jam...

Recent study betw 2018-2023 # of Concierge medicine practices in USA has increased 78.4% (3,935 to 7,021); mostly Texas (402), Calif. (387), Florida (352), Georgia (139). Signif growth of corporate owned practices, increased from 9.2% to 33.8% www.healthaffairs.org/doi/abs/10.1...

Antinuclear Antibodies (ANA) rheumnow.com/video/antinu...

NPs and PAs: Opportunities Outside of the Exam Room Ben Smith, PA-C, Thomasville, GA, discusses scholarly and leadership opportunities for nurse practitioners and physician assistants, as part of RheumNow's "Mission: APP Partners in Care" campaign. rheumnow.com/video/nps-an...

ACR: New findings highlight the urgent need to address the arthritis burden, especially for those facing social and economic challenges. These insights will be featured in Arthritis Care & Research, an ACR journal. buff.ly/IWOD7V9